Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 15;56(24):3271-3276.
doi: 10.2169/internalmedicine.8618-16. Epub 2017 Oct 11.

Management of Osteoporosis in Chronic Kidney Disease

Kosaku Nitta  1 , Aiji Yajima  1 , Ken Tsuchiya  2
Affiliations
Review

Management of Osteoporosis in Chronic Kidney Disease

Kosaku Nitta et al. Intern Med. .

Abstract

Chronic kidney disease (CKD) patients with coexisting osteoporosis are becoming common. Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function. It is generally thought that osteoporosis in G1 to G3 CKD patients can be treated as in non-CKD patients with osteoporosis. In stage 4 or more advanced CKD patients and CKD patients on dialysis with osteoporosis, however, bisphosphonates must be used with caution, bearing in mind the potential development of such disorders as adynamic bone disease. The use of vitamin D preparations in low doses is relatively safe. In postmenopausal women, raloxifene must be administered with caution. When using denosumab, the serum calcium concentrations should be monitored carefully to prevent the development of hypocalcemia, and active vitamin D preparations should be administered concomitantly. The present article provides an overview of the management of osteoporosis in CKD patients.

Keywords: CKD-MBD; SERM; adynamic bone; bisphosphonate; denosumab; osteoporosis.

PubMed Disclaimer

References

    1. Yoshimura N, Muraki S, Oka H, et al. . Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27: 620-628, 2009. - PubMed
    1. Japanese Society of Nephrology Evidence-based practice for the treatment of CKD. Clin Exp Nephrol 13: 537-566, 2009. - PubMed
    1. Chen NX, Moe SM. Pathophysiology of vascular calcification. Current Osteoporos Rep 13: 372-380, 2015. - PubMed
    1. Bover J, Urena-Torres P, Lloret MJ, et al. . Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control PTH and prevetion of progression of cardiovascular calcification. Expert Opin Pharmacother 17: 1363-1373, 2016. - PubMed
    1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795, 2001. - PubMed

MeSH terms